Roche Holding AG Profit Margin 2010-2023 | RHHBY

Current and historical gross margin, operating margin and net profit margin for Roche Holding AG (RHHBY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Roche Holding AG net profit margin as of December 31, 2023 is 0%.
Roche Holding AG Annual Profit Margins
Roche Holding AG Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $65.370B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.775B 118.03
Novo Nordisk (NVO) Denmark $550.845B 45.38
Johnson & Johnson (JNJ) United States $351.202B 13.93
Merck (MRK) United States $317.211B 83.49
AbbVie (ABBV) United States $291.555B 14.82
AstraZeneca (AZN) United Kingdom $211.944B 18.78
Novartis AG (NVS) Switzerland $196.211B 13.59
Pfizer (PFE) United States $143.772B 13.87
Sanofi (SNY) $114.819B 10.34
Innoviva (INVA) United States $0.929B 6.56